World Cancer Day / ASGCR 2023 / Strategies for high quality cancer clinical trials in LMICs
World Cancer Day / ASGCR 2023 / Strategies for high quality cancer clinical trials in LMICs Dear Colleagues, Those who are interested can register for the 11th Virtual ASGCR. Registration is free. You are also encouraged to respond to “Request For Information” (RFI), especially those in the Medical Research Dept.
- World Cancer Day (February 4th, 2023)
Saturday, February 4th, 2023, is World Cancer Day. Join us to help raise awareness of the importance of cancer research that benefits all people – “United we are strong together and can end cancer as we know it”. Please read about the U. S. National Cancer Institute’s Center for Global Health and our work to #CloseTheCareGap. #WorldCancerDay2023 https://bit.ly/3HNOHXT
- The 11th Annual Symposium on Global Cancer Research (ASGCR) (April 4th – 6th, 2023) – registration now open
The 11th Annual Symposium on Global Cancer Research will be held virtually April 4th – 6th, 2023, prior to the 14th Annual Consortium of Universities for Global Health (CUGH) Conference. The theme of ASGCR 2023 is “Closing the Research-to-Implementation Gap” and it will feature presentations on cancer research and control programs that address the global burden of cancer. Registration is free and can be completed at https://events.cancer.gov/cgh/asgcr/registration. Registrants will receive the save-the-date calendar invitation, Zoom link, and periodic updates as the scientific program is finalized. For questions, please contact Mishka Kohli Cira: [email protected]
- Request for Information (RFI): Cancer Therapeutic Clinical Trials in Low- and Middle-Income Countries (Closes March 10th, 2023)
The U.S. National Cancer Institute (NCI) is soliciting input about how to increase high-quality cancer therapeutic clinical trials in low- and middle-income countries (LMICs) as well as the key research priorities for such clinical trials (NOT-CA-23-015: Request for Information (RFI): Cancer Therapeutic Clinical Trials in Low- and Middle-Income Countries (nih.gov)). NCI seeks information and recommendations that will help identify best practices, challenges, and strategies to overcome them, resources, and opportunities to enhance cancer therapeutic clinical trials specifically in LMICs. In the context of this RFI, cancer therapeutic clinical trials include surgical, radiotherapy, chemotherapy, immunotherapy, or other interventions that target a specific cancer type after it develops. NCI seeks comment on any of the subjects listed above and offers the following topics for response:
- Primary challenges or barriers to conducting cancer therapeutic clinical trials in LMICs.
- Successful strategies to overcome or mitigate these challenges.
- Other strategies that might be tried to help address these challenges.
- The role of national and local cancer control priorities in planning and implementing cancer therapeutic clinical trials in LMICs.
- Cultural, ethical, or country-specific obstacles that may impact advancing cancer therapeutic clinical trials in LMIC.
- Components and key characteristics of a highly effective cancer therapeutic clinical trials network in an LMIC setting.
- Specific scientific or disease areas that should be the focus of clinical trial efforts in LMICs.
- Ways in which cancer therapeutic clinical trials in LMICs can impact clinical care and/or reduce cancer mortality.
Responses to this RFI must be submitted electronically at [email protected]. Responses will be accepted through 11:59 p.m. U.S. Eastern Standard Time on March 10, 2023. Please direct all inquiries to: Ophira Ginsburg, MScMD (Senior Advisor for Clinical Research, NCI Center for Global Health; Email: [email protected] ) To view additional information and subscribe to other opportunities at the U.S. National Institutes of Health, please see: Fogarty International Center (nih.gov) and NCI Center for Global Health (CGH) – NCI (cancer.gov)